Management of epilepsy in pregnancy: a report from the International League Against Epilepsy Task Force on Women and Pregnancy
Year: 2019
Type: review
Abstract: The risks associated with use of antiepileptic drugs during pregnancy are a major concern for all women with epilepsy with childbearing potential. These risks have to be balanced against foetal and maternal risks associated with uncontrolled seizures. This report from the International League Against Epilepsy Task Force on Women and Pregnancy aims to provide a summary of relevant data on these risks as a basis for expert opinion recommendations for the management of epilepsy in pregnancy. The report reviews data on maternal and foetal risks associated with seizures as well as teratogenic risks associated with antiepileptic drug exposure, including effects on intrauterine growth, major congenital malformations, and developmental and behavioural outcomes. The impact of pregnancy on seizure control and on the pharmacokinetics of antiepileptic drugs are also discussed. This information is used to discuss how treatment may be optimized before conception and further managed during pregnancy.
Source: Epileptic Disorders
Institutions: Karolinska University Hospital, Karolinska Institutet, Fondazione IRCCS Istituto Neurologico Carlo Besta, Manchester Academic Health Science Centre, University of Manchester, Royal Manchester Children's Hospital, Consejo Nacional de Investigaciones Científicas y Técnicas, Hospital Ramos Mejía, Hospital El Cruce, Stanford University, Brigham and Women's Hospital, Harvard University, Sree Chitra Thirunal Institute for Medical Sciences and Technology
Language: English
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $2,430
Funders: American Epilepsy Society, Epilepsy Foundation, Sanofi, American Academy of Neurology, Sunovion, GW Pharmaceuticals, Upsher-Smith, National Institute for Health and Care Research, Eisai, Stockholms Läns Landsting, NordForsk, Sun Pharma, Epilepsy Society, National Institutes of Health, National Institute of Neurological Disorders and Stroke, UCB Pharma
Awards: G116153085, Scandinavian multi-registry study of antiepileptic drug teratogenicity (SCAN-AED), Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs (MONEAD), Assessment of neurodevelopmental teratological risk in large cohorts: feasibility and reliability of parental reporting methods, G9000351020
OpenAlex ID: W2998717077
